Table 2.
Diagnosis of TB, Provision of TPT, and TPT Outcomes
| Cohort description | Age | Age | Age | Total |
|---|---|---|---|---|
| <5 Years | 5–12 Years | 13–18 Years | ||
| N | 30 | 57 | 25 | 112 |
| TB Diagnosis | ||||
| MDR/RR-TB (based on source patient diagnosis) | 3 (10%) | 6 (11%) | 1 (4%) | 10 (9%) |
| DS-TB (bacteriologically confirmed) | 0 | 1 (2%) | 0 | 1 (1%) |
| Total | 3 (10%) | 7 (13%) | 1 (4%) | 11 (10%) |
| No TPT | 2 | 2 | 2 | 6 |
| TPT Started (Monotherapy Regimen) | ||||
| Levofloxacin (tablets) | 0 | 32 | 18 | 50 |
| Levofloxacin (dispersible/syrup) | 24 | 4 | 0 | 29 |
| Levofloxacin (any formulation) | 24 (96%) | 36 (75%) | 19 (86%) | 79 (83%) |
| Isoniazid | 1 | 5 | 4 | 9 |
| Delamanid | 0 | 7 | 0 | 7 |
| TPT Outcome | ||||
| Completed | 21 (84%) | 37 (77%) | 18 (82%) | 76 (80%) |
| LTFU | 2 (8%) | 6 (13%) | 4 (17%) | 12 (13%) |
| Stopped due to AE | 2 (8%) | 5 (10%) | 0 (0%) | 7 (7%) |
| Total | 25 | 48 | 22 | 95 |
Abbreviations: AE, adverse events; DS-TB, drug-susceptible tuberculosis; LTFU, loss to follow-up; MDR/RR-TB, multidrug- or rifampicin-resistant tuberculosis; TB, tuberculosis; TPT, TB preventive treatment.